MEI Pharma, Inc. (MEIP): Business Model Canvas [Dec-2025 Updated]

You're looking at one of the most dramatic corporate pivots I've seen in my two decades covering this space. Forget the old oncology pipeline; MEI Pharma, Inc. (MEIP) has fundamentally rewired its business model to become a public company treasury focused on digital assets, specifically holding about $110.4 million in Litecoin as of August 2025, now trading under the ticker LITS. This isn't a small side bet; it's a complete shift in risk and revenue profile, moving from drug development to institutional-grade crypto asset management, while still preserving optionality on legacy IP. I've broken down exactly how this new structure functions across all nine blocks of the Business Model Canvas below, so you can see the hard numbers behind this defintely bold strategy.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Key Partnerships

You're looking at the partnerships that define MEI Pharma, Inc.'s (MEIP) dramatic pivot in late 2025. The key relationships now center on institutionalizing Litecoin (LTC) as a treasury asset, a massive shift from its prior focus as a clinical-stage pharmaceutical company. Here's the breakdown of the crucial players supporting this new structure.

GSR for digital asset strategy and risk management

GSR, a crypto market maker and trading firm, is central to MEI Pharma's new financial strategy. They led the capital infusion and now manage the digital assets. This partnership was cemented through a $100 million Private Investment in Public Equity (PIPE) that closed in mid-2025. GSR acts as the digital asset treasury manager, execution partner, and strategic advisor for MEI Pharma's Litecoin treasury. This initiative is the first time a public company is aligning its treasury strategy with Litecoin at an institutional level.

Charlie Lee, Litecoin creator, providing strategic guidance as a board member

Litecoin creator Charlie Lee is a key partner, joining MEI Pharma's Board of Directors following the PIPE, replacing Taheer Datoo. Lee is also a lead investor in the $100 million PIPE. His involvement provides deep technical credibility and a long-term perspective on Litecoin's evolution, which is the core of the company's new treasury focus. The Litecoin Foundation also participated in the investment round.

Digital asset custodians and liquidity providers

While GSR is explicitly named as the digital asset treasury manager, specific, separate third-party custodians or liquidity providers beyond the core investment group have not been detailed in the public announcements regarding the treasury launch. The structure relies on GSR's expertise to manage the asset, which is a significant part of the overall digital asset strategy. For context on the asset itself, as of November 30, 2025, MEI Pharma's 929,548 LTC tokens, purchased at an average price of $107.58, were valued at approximately $115 million, up from the initial $100 million investment.

The investment syndicate supporting this new direction included several notable firms:

• ParaFi
• Hivemind
• Primitive Ventures
• RLH Capital
• Delta Blockchain Fund

Potential biotech partners for out-licensing legacy oncology IP

The strategic review process, which led to the crypto pivot, explicitly considered out-licensing opportunities for existing programs. Before the pivot, MEI Pharma had discontinued clinical development of its core asset, voruciclib. While the new strategy focuses on the digital asset treasury, the legacy oncology pipeline remains an asset that could be monetized through partnerships. In the broader life sciences sector in 2025, 68% of blockbuster drugs now come from licensing deals, indicating a strong market for out-licensing, with co-development agreements seeing a 47% increase in the past 18 months. Specific partners for MEI Pharma's legacy IP are not named as of late 2025, as the focus has shifted to the digital asset mission.

Oppenheimer & Co. as exclusive financial advisor for strategic review

Oppenheimer & Co. Inc. was engaged as the exclusive financial advisor to assist in the process to review and evaluate strategic alternatives, a process initially announced on July 22, 2024. This engagement was a precursor to the current structure and aimed at maximizing stockholder value through options including mergers, acquisitions, or out-licensing. The engagement was announced on August 12, 2024. The firm's role concluded or was superseded by the successful closing of the PIPE in mid-2025, which established the new Litecoin treasury strategy.

Here is a summary of the key financial and structural data related to the primary partnership that defined the late 2025 business model:

Finance: draft updated capitalization table reflecting the PIPE share issuance by Monday.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Key Activities

You're looking at a company that has executed a near-total strategic pivot, moving from a pure-play oncology developer to a digital asset treasury manager, while still holding onto legacy pharmaceutical assets. This shift defines the current Key Activities for Lite Strategy, Inc. (formerly MEI Pharma, Inc.).

Institutional-grade digital asset treasury management

The primary activity now centers on building and maintaining an institutional-grade digital asset treasury. This involves operationalizing the infrastructure to support a large, non-Bitcoin digital asset holding. The strategy was developed in partnership with crypto investment firm GSR, which provides liquidity, risk management, and strategic insight to support the adoption of Litecoin (LTC) as a core treasury asset. This move establishes Lite Strategy, Inc. (NASDAQ: LITS) as the first U.S.-listed public company to adopt Litecoin as its primary reserve asset. The company is focused on expanding access to compliant digital asset exposure while seeking to enhance shareholder value.

Acquiring and holding Litecoin (LTC) as a primary reserve asset

The core of the new business model is the acquisition and holding of Litecoin (LTC). This activity was initiated following the closing of a $100,000,000 private placement of common stock and warrants completed on July 17, 2025. The investment utilized all net proceeds from that placement. The company acquired 929,548 LTC tokens between July 30 and August 4, 2025, at an average price of $107.58 per token. As of August 4, 2025, these Litecoin holdings were valued at approximately $110.4 million. The company cited Litecoin's 13 years of operational uptime, low transaction fees, and broad-based adoption as key reasons for selection.

Here's a quick look at the initial treasury deployment:

The firm indicated plans to formally update its corporate identity in the weeks following the acquisition and may commence LTC mining activities. This treasury strategy is built on digital asset infrastructure and long-term capital innovation.

Corporate governance and NASDAQ compliance (ticker LITS)

A significant governance activity was the formal corporate transition to align with the new strategy. MEI Pharma, Inc. officially changed its corporate name to Lite Strategy, Inc. and its ticker symbol on the NASDAQ Stock Market from MEIP to LITS, effective at market open on September 11, 2025. This required compliance with NASDAQ listing standards under the new structure. Key personnel changes support this shift.

• Litecoin creator Charlie Lee serves on the board of directors.
• GSR is providing strategic insight, and Joshua Riezman, U.S. Chief Strategy Officer of GSR, was welcomed as a new board member.
• The company is focused on ensuring robust governance, execution, and market expertise for its digital asset strategy.

Strategic evaluation of remaining pharmaceutical assets

Lite Strategy, Inc. continues to assess its legacy pharmaceutical portfolio, though the focus has clearly shifted. The company was previously exploring strategic alternatives, including out-licensing opportunities and merger and acquisition deals, with Oppenheimer & Co. serving as the exclusive financial advisor in that process. The pipeline evaluation is ongoing, specifically looking to identify new development opportunities for its drug candidates.

The prior pharmaceutical activities have been rationalized to preserve cash:

• The company holds a portfolio of four clinical-stage assets.
• Zandelisib is in an ongoing Phase 2 clinical trial.
• The clinical development of voruciclib was discontinued.
• Asset ME-344 was sold for $0.5 million upfront plus up to $62.0 million in regulatory and commercial milestones.

Cash preservation efforts and staged reduction-in-force

To fund operations while the strategic alternatives review and new treasury strategy were being established, aggressive cash preservation measures were a critical activity. As of Q1 FY2025, cash, cash equivalents, and short-term investments stood at $26.9 million with no debt, providing management with liquidity sufficient to fund operations for at least the next 12 months. This runway was aided by cost actions, including a staged reduction-in-force. The company reported having 28 employees as of July 2025. The impact of these cost controls is visible in the operating expenses.

The financial results show the effect of these actions, defintely narrowing the net loss:

The Q3 FY2025 cash position, reported as of March 31, 2025, was $20.5 million in cash and cash equivalents, with no outstanding debt. Finance: draft 13-week cash view by Friday.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Key Resources

You're looking at the core assets Lite Strategy, Inc. (formerly MEI Pharma, Inc.) is relying on as it pivots its focus, so let's break down what's on the books and what's in the intellectual vault right now.

The most prominent new resource is the digital asset holding. Lite Strategy, Inc. became the first U.S.-listed public company to adopt Litecoin (LTC) as a primary reserve asset following a significant private placement. This move is central to the new business structure.

The company's financial foundation, separate from the digital assets, is anchored by its traditional cash position, though the focus has clearly shifted. The team managing this pivot is a key resource, bringing in specialized expertise for the new digital asset strategy.

Here's a quick look at the hard numbers underpinning these resources as of the latest available data:

The intellectual property portfolio, while historically the main focus, now supports the legacy business while the digital asset strategy takes the lead. You need to know what's still on the shelf regarding the oncology pipeline.

• Intellectual property covering voruciclib, an oral selective CDK9 inhibitor.
• Intellectual property for zandelisib, a selective PI3Kδ inhibitor.
• Development efforts for voruciclib ceased as of July 22, 2024, but the company continues to evaluate development opportunities for both candidates.

The management structure supporting the digital asset component is a critical, non-tangible resource. This team is what makes the LTC treasury strategy operational and compliant for a public entity. It's definitely a new kind of resource for a company with a pharma background.

Key personnel and advisory relationships include:

• Charlie Lee, Creator of Litecoin, serving as a member of the Board of Directors.
• GSR, a global leader in digital asset treasury capital markets, appointed as the treasury management advisor.
• Jay File, Acting CEO of Lite Strategy, Inc.

Finally, the public listing itself is a resource, granting access to capital markets that private digital asset companies don't have. The transition to the NASDAQ ticker LITS, effective September 11, 2025, solidifies this access under the new corporate identity.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Value Propositions

You're looking at a company that has fundamentally shifted its core value proposition from clinical-stage oncology to pioneering digital asset treasury management. Here are the hard numbers underpinning that new value proposition as of late 2025.

Unique public company exposure to a Litecoin-focused treasury strategy

Lite Strategy, Inc. (formerly MEI Pharma, Inc. (MEIP)) became the first U.S.-listed public company to adopt Litecoin (LTC) as a primary reserve asset following a major strategic pivot announced in August 2025. This strategy was initiated by deploying the net proceeds from a private placement completed on July 17, 2025. The company formally changed its ticker to LITS effective at market open on September 11, 2025, aligning its identity with its new focus.

• Gross proceeds raised from the private placement: $100 million.
• Price per share in the private placement: $3.42.
• Number of LTC tokens acquired: 929,548.
• Average purchase price per LTC token: $107.58.

Potential for capital appreciation from digital asset holdings

The value proposition here is direct exposure to the performance of a significant digital asset holding, guided by Litecoin Creator Charlie Lee and asset manager GSR. The initial investment immediately represented a substantial asset base on the balance sheet.

The market reacted to this announcement; over the month preceding the August 5, 2025 disclosure, MEIP shares jumped 111% against the U.S. dollar.

Preservation of capital via a highly liquid, debt-free balance sheet

A key component of the strategy was ensuring the new digital asset allocation was built on a foundation of liquidity and no leverage. This is a critical differentiator when many biotech firms carry significant debt loads. As of the end of the third quarter of fiscal year 2025, the balance sheet supported this claim, though the company's net debt position showed movement later in the year.

• Cash and cash equivalents as of March 31, 2025: $20.5 million.
• Outstanding debt as of March 31, 2025: no outstanding debt.
• Net Debt (LTM as of Sep 29, 2025): ($10.1M).

The company was described as having an adequate balance sheet, which is definitely a plus.

Optionality value from a small, de-prioritized oncology pipeline

The company has not completely abandoned its legacy pharmaceutical assets, but the focus has clearly shifted. The remaining pipeline assets are being assessed for preclinical strategy development, not active clinical trials, suggesting a low-cost, high-optionality approach to these assets.

• Drug candidates being evaluated for a preclinical strategy: 2 (voruciclib and zandelisib).
• Clinical activities related to voruciclib were discontinued following July 2024.
• Voruciclib is an oral cyclin-dependent kinase 9 inhibitor.
• Zandelisib is an oral, selective PI3Kδ inhibitor.
• Employee count as of July 2025: 28 employees.

Pioneering institutional adoption of digital assets in corporate finance

Lite Strategy, Inc. established itself as a first-mover, creating a blueprint for other public companies looking to integrate compliant digital assets into their corporate treasury. This pioneering status is supported by the involvement of key industry figures and firms in the execution of the strategy.

• The strategy is guided by Litecoin Creator Charlie Lee, who joined the Board of Directors.
• The treasury is managed by GSR, a digital asset market maker.
• The company is exploring commencement of Litecoin mining activities.

Finance: draft 13-week cash view by Friday.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Customer Relationships

You're looking at a company that has made a dramatic pivot, so the customer relationships are now split between legacy financial stakeholders and the new digital asset community. The focus has shifted from clinical trial participants and prescribing physicians to shareholders and crypto partners.

Investor Relations (IR) focused on communicating the new digital asset strategy

Investor Relations communications for MEI Pharma, Inc., which officially became Lite Strategy, Inc. (LITS) on September 11, 2025, are now entirely centered on the Litecoin (LTC) treasury strategy. The primary communication event was the announcement of the $100 million private placement in July 2025, which funded the initial purchase of the digital asset. The IR function is now tasked with explaining the new corporate identity and the shift from a NASDAQ ticker of MEIP to LITS.

The company reports its financial standing transparently to public markets, noting that as of March 31, 2025, it held $20.5 million in cash and cash equivalents with zero outstanding debt. Post-pivot, the company introduced a new key metric for shareholders: the LITS Treasury NAV Per Share, which is calculated using the value of its LTC holdings.

Key financial and strategic data points for the relationship management are:

Transactional, B2B relationship with potential IP buyers/licensees

The legacy B2B relationship centers on the remaining pharmaceutical intellectual property (IP). The company continues to evaluate strategic alternatives, including out-licensing opportunities for existing programs, with Oppenheimer & Co., Inc. serving as the exclusive financial advisor in this process. This relationship is purely transactional, focused on maximizing asset value from the prior biotech model.

Lite Strategy, Inc. indicated it continues to evaluate its pipeline, which includes the drug candidates voruciclib and zandelisib. The company is looking to identify new development opportunities for these assets, which implies seeking B2B partners for future development or acquisition.

Direct engagement with digital asset community and stakeholders

Direct engagement is high-profile and focused on legitimizing the new digital asset strategy. This relationship is built on the credibility of key partners brought in during the $100 million private placement. The community engagement is less about mass marketing and more about institutional signaling.

• Charlie Lee, Litecoin creator, joined the Board of Directors.
• GSR, a prominent digital asset market maker, was appointed as the treasury's Asset Manager.
• The company positioned itself as the first U.S.-listed public company to adopt LTC for its corporate treasury.
• The company's mission is to be the bridge between the people's currency and millions who deserve access to it.

Minimal patient/physician engagement due to discontinued clinical trials

Engagement with patients and physicians, the core customer base of the former pharmaceutical business, is now minimal. This is a direct result of the strategic shift. The company confirmed the discontinuation of all clinical activities related to voruciclib following a failed merger attempt in July 2024. While the company still evaluates its pipeline, the operational focus has moved away from active clinical development, meaning the traditional patient/physician relationship structure has largely dissolved.

Transparent financial reporting to public markets

The commitment to transparent reporting remains, though the focus of the reporting has changed. The company reports quarterly figures, such as the $20.5 million cash position as of March 31, 2025. The new public reporting framework emphasizes metrics related to the digital asset treasury, such as the total number of LTC held and the calculated Treasury NAV Per Share. The stock, trading under the ticker LITS, has seen volatility, with a reported price as low as $0.07 in September 2025, reflecting the market's assessment of the high-risk pivot, despite a July 2025 Market Cap of $39.44M.

The company explicitly lists risks to investors in its filings, including fluctuations in the market price of LTC and potential impairment charges if the price of LTC falls below its carried value on the balance sheet. Finance: draft 13-week cash view by Friday.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Channels

You're looking at how Lite Strategy, Inc., formerly MEI Pharma, Inc., gets its message and its assets to the market as of late 2025. The channels have definitely shifted from purely biotech focus to a dual-track approach, balancing traditional pharma disclosures with a very public digital asset treasury strategy.

The primary avenues for capital access and market visibility are now split between public equity markets and the digital asset ecosystem. Here's a look at the hard numbers defining these channels.

For corporate disclosures and regulatory filings, the company still relies on established pipelines, though the focus has clearly pivoted. The corporate website and investor relations portals are the official source for these documents.

• Quarterly Cash Position (e.g., Q3 FY2025 ending March 31, 2025): $20.5 million in cash and cash equivalents.
• Total Employees (as of July 2025): 28.
• Strategic Alternatives Review Advisor: Oppenheimer & Co., Inc.
• Corporate Identity Update: Planned formal update in the weeks following August 2025 to reflect the new strategy.

Market awareness is driven by traditional financial media, but the new digital asset focus has brought in specialized crypto outlets. Analyst coverage now reflects this dual nature, though the overall stock score from TipRanks' AI Analyst, Spark, was rated as Neutral.

• Key Media Outlets Reporting: Business Wire, Nasdaq, The Block, Bitcoin.com News.
• Stock Performance Driver (July 18, 2025): Stock trending up by 33.11% following news of the Litecoin treasury strategy.
• Reported Revenue Decline (Trailing Twelve Months): Drastic declines, dropping by 100% over three-year and five-year periods.

Direct communication with institutional investors remains crucial, especially following the capital raise and strategic shift. The 13F filings give us a snapshot of who is actively engaging with the equity side of the business.

• Institutional Owners (as of Sept 10, 2025): 62 firms filing 13D/G or 13F forms.
• Total Shares Held by Institutions (as of Sept 10, 2025): 10,214,299 shares.
• Largest Institutional Holders Include: Citadel Advisors Llc, Renaissance Technologies Llc.
• Board Changes: Charlie Lee, Creator of Litecoin, joined the Board of Directors.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Customer Segments

The customer segments for Lite Strategy, Inc. (formerly MEI Pharma, Inc. (MEIP)) are now bifurcated, reflecting the strategic pivot from a pure-play oncology focus to a digital asset treasury strategy, while still retaining residual interest from former biotech stakeholders.

Institutional and retail investors seeking exposure to digital assets

This segment is attracted by the company becoming the first U.S.-listed public company to adopt Litecoin (LTC) as its primary reserve asset following a $100 million private placement in July 2025. The retail investor interest was noted by sentiment trending to the 'extremely bullish' territory on Stocktwits following the announcement.

Key figures related to the digital asset holdings and investor base include:

• Aggregate gross proceeds from the PIPE transaction: approximately $100 million.
• LTC treasury value as of August 4, 2025: approximately $110.4 million.
• Number of LTC tokens acquired: 929,548.
• Average acquisition price per LTC token: $107.58.
• Institutional owners filing 13D/G or 13F forms: 62.
• Total shares held by these institutions: 10,214,299 shares.
• Institutional Ownership percentage (as MEIP): 8.13%.

Speculative investors focused on the strategic pivot and LTC price

This group is betting on the success of the new corporate strategy under the Lite Strategy, Inc. banner, with the stock performance becoming directly correlated with the Litecoin price, creating a 'MicroStrategy-for-Litecoin' model. The stock traded at $0.07 at one point post-rebrand announcement, down over 70% year-to-date from a prior price point.

The financial health metrics that influence speculative sentiment include:

Biotech and pharmaceutical companies interested in acquiring oncology IP

While the company has discontinued clinical development for voruciclib and sold ME-344, the residual intellectual property (IP) and data packages still represent potential value for M&A or out-licensing, as part of the ongoing strategic alternatives review. The company previously had a portfolio including zandelisib, voruciclib, and ME-344.

Key financial data related to the divestiture of the former core assets:

• Upfront payment received for ME-344 sale: $0.5 million.
• Total potential milestone payments for ME-344: up to $62.0 million.
• R&D Expense in Q1 FY2025 (post-discontinuation): $3.163 million.
• R&D Expense in Q2 FY2024 (pre-pivot): $3.485 million.

Financial technology (FinTech) innovators and blockchain enthusiasts

This segment is engaged by the company's pioneering status as the first U.S.-listed public company to use Litecoin as a corporate treasury reserve asset. The involvement of Charlie Lee, the creator of Litecoin, on the board, and GSR as the treasury management advisor, directly targets this group.

The transaction structure that appeals to this segment includes:

• Share price in the PIPE transaction: $3.42 per share.
• The company's new ticker symbol: LITS, effective September 11, 2025.
• The company's new corporate name: Lite Strategy, Inc..

Former biotech investors seeking a defintely different value proposition

These investors are those who held MEI Pharma (MEIP) prior to the July 2025 strategic shift and are now evaluating the company based on its new structure, which offers exposure to a digital asset without the typical clinical trial risk profile. The company's market capitalization was reported as $100.82M USD at one point, contrasting with the later reported micro-cap valuation of $660,000.

Data points reflecting the shift in operational focus:

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Cost Structure

You're looking at the cost structure for the company formerly known as MEI Pharma, Inc., which rebranded to Lite Strategy, Inc. (LITS) effective September 11, 2025, following its pivot to a digital asset treasury strategy. The cost profile reflects significant restructuring and a shift in focus away from primary drug development activities as of late 2025.

The most recent concrete operational expenses available are from the third quarter of fiscal year 2025, ending March 31, 2025, which show substantial cost discipline following prior strategic reviews.

Here's a quick look at the key operating expense components for Q3 FY2025:

The Selling, General and Administrative (SG&A) expense figure of $2.40 million in Q3 FY2025 represents a significant reduction from the $4.60 million reported in Q3 2024, showing the impact of cost-saving measures like the reduction-in-force mentioned in earlier reports.

Research and Development (R&D) costs have also reset materially lower, with the Q3 FY2025 figure of $369,000 ($0.369 million) being a sharp drop from the $5.22 million recorded in the prior year's third quarter, reflecting the strategic decision to initiate a preclinical strategy for voruciclib and zandelisib rather than active late-stage development.

The cost structure going forward into late 2025 must account for new, non-traditional expenses related to the digital asset strategy, though specific figures for these are not yet itemized in the same way as traditional operating expenses:

• Digital asset custody, security, and risk management fees, with GSR guiding execution and risk management for the Litecoin treasury.
• Legal and accounting costs related to public company compliance and the rebrand from MEI Pharma, Inc. to Lite Strategy, Inc..
• Severance and restructuring costs from the reduction-in-force implemented as part of cash preservation efforts.

The company's cash position as of March 31, 2025, was $20.5 million in cash and cash equivalents with no outstanding debt, which management aimed to extend through these cost-cutting measures.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for MEI Pharma, Inc., now Lite Strategy, Inc., as it pivots hard into digital asset treasury management in late 2025. The traditional pharmaceutical revenue model is currently on pause, so the focus shifts entirely to capital structure activities.

The primary financial activity driving near-term value is the execution of the new treasury strategy, which was funded by a significant equity raise.

• Proceeds from private placement offerings: $100 million gross proceeds secured in July 2025 from the sale of 29,239,767 shares of common stock or pre-funded warrants at $3.42 per share. The company reported receiving $99.999401 million in funding from various investors.
• Potential capital gains/losses from the Litecoin (LTC) treasury strategy: The strategy involves holding the acquired LTC as the primary treasury reserve asset. As of August 4, 2025, the 929,548 Litecoin (LTC) tokens acquired were valued at approximately $110.4 million, based on an average purchase price of $107.58 per LTC.
• Potential one-time payments from out-licensing or sale of drug candidates: Management is actively engaged in evaluating strategic alternatives, which include out-licensing and merger possibilities. No specific dollar amounts for realized payments are available as of this time.

The legacy revenue stream from drug sales is currently reporting zero, reflecting the company's strategic shift away from immediate clinical execution toward capital management.

Interest income from cash and short-term investments is a minor component compared to the treasury strategy. For context on liquidity before the PIPE, cash and cash equivalents stood at $23.7 million at the end of Q2 FY2025 (December 31, 2024), with previous short-term investments of $19.95 million (Q1) moved into cash. Any interest earned on this cash balance would be minimal relative to the potential capital movements in the LTC treasury.

Here's the quick math: The $100 million raise was immediately deployed into an asset valued at $110.4 million shortly after, suggesting an immediate paper gain or a difference in spot pricing versus the PIPE price, which is the core of the potential capital gains stream. What this estimate hides is the ongoing volatility of the Litecoin asset itself, which dictates the realized gain or loss.

• Key Stakeholders in New Revenue Stream:
• Charlie Lee joined the Board of Directors.
• GSR appointed as digital asset and treasury management advisor.
• Litecoin Foundation participated in the funding round.